Anonymous
Guest
Anonymous
Guest
Scientific fraud Master!!!
"Pharmalot: In your view, what was the most compelling take away from this whole episode?
Prakash: I think what really shocked me was the extent of the scientific manipulation. It had never occurred to me, and it’s probably quite naïve. I knew the tobacco industry played with science and I knew about accounting and financial fraud, because I had been a banking reporter. I understood about cooking numbers. But I didn’t understand about manipulating clinical trial data and couldn’t believe a company of Merck’s stature could be doing that. …I turned to epidemiologists and cardiologists and asked all these questions that a reporter asks. All these stupid questions. And I kept coming up against the fact that this very big company was really not treating people and human lives in the way you would expect them to. And you look around at the cultural and social landscape and you see, well, what I learned from covering litigation and trials before that is how hard it is to hold powerful corporate actors to account.
Read the whole story:
http://www.pharmalot.com/2011/06/merck-vioxx-and-the-legal-system-snigdha-explains/
"Pharmalot: In your view, what was the most compelling take away from this whole episode?
Prakash: I think what really shocked me was the extent of the scientific manipulation. It had never occurred to me, and it’s probably quite naïve. I knew the tobacco industry played with science and I knew about accounting and financial fraud, because I had been a banking reporter. I understood about cooking numbers. But I didn’t understand about manipulating clinical trial data and couldn’t believe a company of Merck’s stature could be doing that. …I turned to epidemiologists and cardiologists and asked all these questions that a reporter asks. All these stupid questions. And I kept coming up against the fact that this very big company was really not treating people and human lives in the way you would expect them to. And you look around at the cultural and social landscape and you see, well, what I learned from covering litigation and trials before that is how hard it is to hold powerful corporate actors to account.
Read the whole story:
http://www.pharmalot.com/2011/06/merck-vioxx-and-the-legal-system-snigdha-explains/